Role of CCL2 in Alcoholic Liver Diseases

May 20, 2010 updated by: Erasme University Hospital
Immune dysregulations, including cytokines and chemokines secretions occurs in alcoholic liver disease. Serum levels and liver expression of CCL2 are increased in patients with alcoholic hepatitis but the role of this chemokine in the pathogenesis of alcoholic liver disease is nevertheless unknown. The aim of the study is to analyze plasma level and liver expression of CCL2 and their relation with liver disease severity and inflammatory infiltrate in our cohort of alcoholic patients. We studied also the association between -2518 CCL2 polymorphism and the severity of alcoholic liver disease.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Consecutive patients undergoing transjugular liver biopsy for alcoholic liver disease will be include in the study to measure plasma levels and hepatic expression of CCL2. We determine also the rs1024611 polymorphism of these patients. All these parameters are correlated to severity of the disease.

The frequency of the presence of this polymorphism was also compared to a population of healthy subjects.

Description

ALD patients

Inclusion Criteria:

  • Excess alcohol intake
  • Abnormality of liver biopsy compatible with alcoholic aetiology
  • Caucasian ethnicity

Exclusion Criteria:

  • Presence of any other chronic liver disease
  • co-infection with HIV Controls Inclusion criteria
  • Caucasian ethnicity
  • presence of a disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
alcoholic liver disease
alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
controls
Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Erasme University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted

May 20, 2010

First Submitted That Met QC Criteria

May 20, 2010

First Posted (Estimate)

May 21, 2010

Study Record Updates

Last Update Posted (Estimate)

May 21, 2010

Last Update Submitted That Met QC Criteria

May 20, 2010

Last Verified

December 1, 2002

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DD-CCL2

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe